Long-term safety and efficacy of rilonacept in patients with systemic juvenile idiopathic arthritis

Arthritis and Rheumatism

Volumn 65, Issue 9, 2013, Pages 2486-2496

  Lovell, Daniel J ^a   Giannini, Edward H ^a   Reiff, Andreas O ^b   Kimura, Yukiko ^c   Li, Suzanne ^c   Hashkes, Philip J ^d   Wallace, Carol A ^e   Onel, Karen B ^f   Foell, Dirk ^g   Wu, Richard ^h   Biedermann, Stephanie ^h   Hamilton, Jennifer D ^h   Radin, Allen R ^h  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b CHILDREN S HOSPITAL LOS ANGELES   (United States)

^c HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^d SHAARE ZEDEK MEDICAL CENTER   (Israel)

^e SEATTLE CHILDREN S HOSPITAL   (United States)

^f UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^g UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^h REGENERON PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; D DIMER; MEMBRANE PROTEIN; METHOTREXATE; MYELOID RELATED PROTEIN 14; MYELOID RELATED PROTEIN 8; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PREDNISONE; RILONACEPT; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; CHILD; CHILDHOOD HEALTH ASSESSMENT QUESTIONNAIRE; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DISEASE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EAR INFECTION; FEMALE; FEVER; HORDEOLUM; HUMAN; INFLUENZA; INJECTION SITE BLEEDING; INJECTION SITE CONTUSION; INJECTION SITE DESQUAMATION; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE REACTION; INJECTION SITE SWELLING; JUVENILE RHEUMATOID ARTHRITIS; MALE; PANCYTOPENIA; PHASE 2 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RASH; RHINOPHARYNGITIS; SCHOOL CHILD; SKIN INFECTION; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; VIRAL GASTROENTERITIS;

ADOLESCENT; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE; CHILD; CHILD, PRESCHOOL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; RECOMBINANT FUSION PROTEINS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84883233255     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.38042     Document Type: Article

References (40)

1. De Benedetti F, Schneider R,. Systematic juvenile idiopathic arthritis. In:, Cassidy JT, Petty RE, Laxer RM, Lindsley CB, editors. Textbook of pediatric rheumatology. 6th ed. Philadelphia: Saunders Elsevier; 2011. p. 236-48.
2. Woo P,. Systemic juvenile idiopathic arthritis: diagnosis, management, and outcome. Nat Clin Pract Rheumatol 2006; 2: 28-34.
3. Mellins ED, Macaubas C, Grom AA,. Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions. Nat Rev Rheumatol 2011; 7: 416-26.
4. Batthish M, Schneider R, Ramanan A, Achonu C, Young NL, Feldman BM,. What does 'active disease' mean? Patient and parent perceptions of disease activity in the systemic arthritis form of juvenile idiopathic arthritis (SO-JIA). Rheumatology (Oxford) 2005; 44: 796-9.
5. Ramanan A, Schneider R, Batthish M, Achonu C, Ota S, McLimont M, et al. Developing a disease activity tool for systemic-onset juvenile idiopathic arthritis by international consensus using the Delphi approach. Rheumatology (Oxford) 2005; 44: 1574-8.
6. Consolaro A, Ruperto N, Bazso A, Pistorio A, Magni-Manzoni S, Filocamo G, et al, for the Paediatric Rheumatology International Trials Organization. Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis Rheum 2009; 61: 658-66.
7. Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A,. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997; 40: 1202-9.
8. Hashkes PJ, Laxer RM,. Medical treatment of juvenile idiopathic arthritis. JAMA 2005; 294: 1671-84.
9. Quartier P, Taupin P, Bourdeaut F, Lemelle I, Pillet P, Bost M, et al. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum 2003; 48: 1093-101.
10. Horneff G, Schmeling H, Biedermann T, Foeldvari I, Ganser G, Girschick HJ, et al, for the Paediatric Rheumatology Collaborative Group. The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann Rheum Dis 2004; 63: 1638-44.
11. Kimura Y, Pinho P, Walco G, Higgins G, Hummell D, Szer I, et al. Etanercept treatment in patients with refractory systemic onset juvenile rheumatoid arthritis. J Rheumatol 2005; 32: 935-42.
12. De Benedetti F, Brunner H, Allen R, Brown D, Chaitow J, Pardeo M, et al. Tocilizumab is efficacious in patients with systemic juvenile idiopathic arthritis across baseline demographic and disease characteristics and prior/baseline treatments: 52-week data from a phase 3 clinical trial [abstract]. Arthritis Rheum 2011; 63 Suppl: S1029-30.
13. Beukelman T, Patkar NM, Saag KG, Tolleson-Rinehart S, Cron RQ, Morgan DeWitt E, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken) 2011; 63: 465-82.
14. Dinarello CA,. Blocking IL-1 in systemic inflammation. J Exp Med 2005; 201: 1355-9.
15. Pascual V, Allantaz F, Arce E, Punaro M, Banchereau J,. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 2005; 201: 1479-86.
16. Verbsky JW, White AJ,. Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis. J Rheumatol 2004; 31: 2071-5.
17. Lachmann HJ, Lowe P, Felix SD, Rordorf C, Leslie K, Madhoo S, et al. In vivo regulation of interleukin 1β in patients with cryopyrin-associated periodic syndromes. J Exp Med 2009; 206: 1029-36.
18. Dinarello CA,. Biologic basis for interleukin-1 in disease. Blood 1996; 87: 2095-147.
19. Economides AN, Carpenter LR, Rudge JS, Wong V, Koehler-Stec EM, Hartnett C, et al. Cytokine traps: multi-component, high-affinity blockers of cytokine action. Nat Med 2003; 9: 47-52.
20. Arcalyst [rilonacept] prescribing information. Tarrytown (NY): Regeneron Pharmaceuticals; 2010.
21. Reiff A,. The use of anakinra in juvenile arthritis. Curr Rheumatol Rep 2005; 7: 434-40.
22. Zeft A, Hollister R, LaFleur B, Sampath P, Soep J, McNally B, et al. Anakinra for systemic juvenile arthritis: the rocky mountain experience. J Clin Rheumatol 2009; 15: 161-4.
23. Nigrovic PA, Mannion M, Prince FH, Zeft A, Rabinovich CE, van Rossum MA, et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum 2011; 63: 545-55.
24. Singh G, Athreya BH, Fries JF, Goldsmith DP,. Measurement of health status in children with juvenile rheumatoid arthritis. Arthritis Rheum 1994; 37: 1761-9.
25. Wallace CA, Ruperto N, Giannini E,. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol 2004; 31: 2290-4.
26. Frosch M, Ahlmann M, Vogl T, Wittkowski H, Wulffraat N, Foell D, et al. The myeloid-related proteins 8 and 14 complex, a novel ligand of Toll-like receptor 4, and interleukin-1β form a positive feedback mechanism in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2009; 60: 883-91.
27. Frosch M, Vogl T, Seeliger S, Wulffraat N, Kuis W, Viemann D, et al. Expression of myeloid-related proteins 8 and 14 in systemic-onset juvenile rheumatoid arthritis. Arthritis Rheum 2003; 48: 2622-6.
28. Frosch M, Strey A, Vogl T, Wulffraat NM, Kuis W, Sunderkotter C, et al. Myeloid-related proteins 8 and 14 are specifically secreted during interaction of phagocytes and activated endothelium and are useful markers for monitoring disease activity in pauciarticular-onset juvenile rheumatoid arthritis. Arthritis Rheum 2000; 43: 628-37.
29. Holzinger D, Frosch M, Kastrup A, Prince FH, Otten MH, Van Suijlekom-Smit L, The Toll-like receptor 4 agonist MRP8/14 protein complex is a sensitive indicator for disease activity and predicts relapses in systemic-onset juvenile idiopathic arthritis W, et al. Ann Rheum Dis 2012; 71: 974-80.
30. Bloom BJ, Alario AJ, Miller LC,. Persistent elevation of fibrin D-dimer predicts longterm outcome in systemic juvenile idiopathic arthritis. J Rheumatol 2009; 36: 422-6.
31. Bloom BJ, Tucker LB, Miller LC, Schaller JG,. Fibrin D-dimer as a marker of disease activity in systemic onset juvenile rheumatoid arthritis. J Rheumatol 1998; 25: 1620-5.
32. Terkeltaub R, Sundy JS, Schumacher HR, Murphy F, Bookbinder S, Biedermann S, et al. The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study. Ann Rheum Dis 2009; 68: 1613-7.
33. Hoffman HM, Throne ML, Amar NJ, Sebai M, Kivitz AJ, Kavanaugh A, et al. Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum 2008; 58: 2443-52.
34. Winthrop KL,. Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor. Nat Clin Pract Rheumatol 2006; 2: 602-10.
35. Furst DE,. The risk of infections with biologic therapies for rheumatoid arthritis. Semin Arthritis Rheum 2010; 39: 327-46.
36. Gattorno M, Piccini A, Lasiglie D, Tassi S, Brisca G, Carta S, et al. The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2008; 58: 1505-15.
37. Ruperto N, Quartier P, Wulffraat N, Woo P, Ravelli A, Mouy A, et al, for the Paediatric Rheumatology International Clinical Trials Organisation. A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. Arthritis Rheum 2012; 64: 557-67.
38. Quartier P, Allantaz F, Cimaz R, Pillet P, Messiaen C, Bardin C, et al. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis 2011; 70: 747-54.
39. Ilowite N, Porras O, Reiff A, Rudge S, Punaro M, Martin A, et al. Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study. Clin Rheumatol 2009; 28: 129-37.
40. Thornton J, Beresford MW, Clayton P,. Improving the evidence base for treatment of juvenile idiopathic arthritis: the challenge and opportunity facing the MCRN/ARC Paediatric Rheumatology Clinical Studies Group [editorial]. Rheumatology (Oxford) 2008; 47: 563-6.